Related Experiment Video
Updated: Aug 11, 2026

Study of the DNA Damage Checkpoint using Xenopus Egg Extracts
Published on: November 5, 2012
Geldanamycin-induced degradation of Chk1 is mediated by proteasome
M Nomura1, N Nomura, J Yamashita
1Department of Neurosurgery, Yokohama Sakae Kyosai Hospital, Yokohama, Japan. nomura413jp@yahoo.co.jp
Abstract:
Checkpoint kinase 1 (Chk1) is a cell cycle regulator and a heat shock protein 90 (Hsp90) client. It is essential for cell proliferation and survival. In this report, we analyzed the mechanisms of Chk1 regulation in U87MG glioblastoma cells using Geldanamycin (GA), which interferes with the function of Hsp90. GA reduced Chk1 protein level but not its mRNA level in glioblastoma cells. Co-treatment with GA and cycloheximide (CHX), a protein synthesis inhibitor, induced a decrease of half-life of the Chk1 protein to 3h and resulted in Chk1 down-regulation. CHX alone induced only 32% reduction of Chk1 protein even after 24h. These findings indicated that reduction of Chk1 by GA was due to destabilization and degradation of the protein. In addition, GA-induced down-regulation of Chk1 was reversed by MG132, a specific proteasome inhibitor. And it was revealed that Chk1 was ubiquitinated by GA. These results have indicated that degradation of Chk1 by GA was mediated by the ubiquitin-proteasome pathway in U87MG glioblastoma cells.
Insights
Geldanamycin (GA) reduces Chk1 protein levels in glioblastoma cells by promoting its degradation via the ubiquitin-proteasome pathway, not by affecting its mRNA. This Hsp90 inhibitor destabilizes Chk1, leading to its breakdown.
Area of Science:
- Molecular Biology
- Cancer Cell Biology
- Biochemistry
Background:
- Checkpoint kinase 1 (Chk1) is a crucial cell cycle regulator and a client of heat shock protein 90 (Hsp90).
- Chk1 plays a vital role in cell proliferation and survival, making its regulation a key area of cancer research.
Purpose of the Study:
- To investigate the mechanisms by which Geldanamycin (GA), an Hsp90 inhibitor, regulates Chk1 protein levels in U87MG glioblastoma cells.
- To determine if GA-induced Chk1 reduction involves changes in mRNA levels or protein degradation pathways.
Main Methods:
- Treatment of U87MG glioblastoma cells with Geldanamycin (GA) and cycloheximide (CHX).
- Analysis of Chk1 protein and mRNA levels.
- Determination of Chk1 protein half-life.
- Investigation of the role of the ubiquitin-proteasome pathway using MG132 and ubiquitination assays.
Main Results:
- Geldanamycin (GA) significantly reduced Chk1 protein levels without affecting its mRNA levels in glioblastoma cells.
- Co-treatment with GA and cycloheximide (CHX) decreased Chk1 protein half-life to 3 hours, indicating protein destabilization.
- GA-induced Chk1 down-regulation was reversed by the proteasome inhibitor MG132, and Chk1 was found to be ubiquitinated in the presence of GA.
Conclusions:
- Geldanamycin (GA) down-regulates Chk1 protein in U87MG glioblastoma cells primarily through destabilization and degradation.
- The degradation of Chk1 induced by GA is mediated by the ubiquitin-proteasome pathway.
- These findings highlight a novel mechanism for targeting Chk1 in glioblastoma therapy.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Inhibition of Cdk Activity
Anaphase Promoting Complex
Export of Misfolded Proteins out of the ER
DNA Damage Can Stall the Cell Cycle

